Inhibrx Biosciences, Inc. (INXB) Stock

About Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. operates as a clinical-stage biopharmaceutical entity, primarily focused on developing advanced biologic treatments for critical, life-threatening medical conditions. Key assets within its development pipeline include: INBRX-109, a tetravalent investigational therapy, is progressing through Phase 2 clinical trials. It is specifically engineered to target death-receptor 5 for the management of advanced, unresectable, or metastatic conventional chondrosarcoma. INBRX-106, a hexavalent sdAb-based investigational treatment targeting OX4, is also in Phase 2 clinical development. This candidate is being evaluated for its potential to treat a diverse array of metastatic solid tumors, encompassing non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancers, renal cell carcinoma, and urothelial (transitional) cell carcinoma. Established in 2024, Inhibrx Biosciences maintains its headquarters in La Jolla, California.

Inhibrx Biosciences, Inc. is headquartered in US.

Inhibrx Biosciences, Inc. (INXB) stock trades at $15.86 with a market capitalization of $225.87M. The stock is valued at a negative price-to-earnings (P/E) ratio of -12.41, reflecting a net loss over the last twelve months, a negative price-to-book of -32.59, reflecting negative shareholders' equity, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $12.95 and $18.95, and currently trades 16.3% below its 52-week high.

On profitability, Inhibrx Biosciences, Inc. generates a return on equity (ROE) of -563.89% (not meaningful, as shareholders' equity is negative), return on capital employed of -101.31%.

Official website: inhibrx.com